Medicare Compliance & Reimbursement - 2007 Issue 25
REIMBURSEMENT: OIG Wants To Squeeze Your Drug Payments Further
Subscribe or sign in to view the full article.
Article Overview
This article reviews an OIG analysis of Medicare Part B drug payment levels in relation to wholesale pricing and explains why the findings could affect future reimbursement policy. It is relevant to billing, coding, compliance, and reimbursement professionals who monitor drug payment methodology, federal oversight reports, and proposed savings targets. The article also summarizes CMS’s response to the OIG’s findings and highlights the broader payment-policy context.
Why This Topic Matters
Part B drug payment policy can affect provider reimbursement, compliance planning, and budget forecasting. Articles like this help readers track federal scrutiny of drug pricing and understand which payment categories are drawing attention from policymakers.
What You Will Learn
- How federal oversight is comparing Medicare Part B drug payment amounts with wholesale acquisition data
- Why certain Part B drug payment categories are attracting policy attention
- How CMS is responding to OIG concerns about payment variability and data timeliness
- How reimbursement scrutiny can influence broader Medicare payment discussions
Who Should Read This
- Medical coders
- Billing staff
- Revenue cycle professionals
- Compliance officers
- Practice administrators
- Reimbursement specialists
Codes Discussed
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com